They also suggested that PARP inhibition, which did not cause severe bone marrow toxicity, might represent an interesting alternative or complement to platinum-based chemotherapy in combination with anti–PD-(L)1 agents in NSCLC. This evidence concerns the gene PARP1 and non-small cell lung carcinoma.